Faculty Fellowships in Public Health Law – Call for Applications

Applications are invited for 10 faculty fellowships in public health law education.

DESCRIPTION 

Georgia State University College of Law and its Center for Law, Health & Society are leading an initiative funded by the Robert Wood Johnson Foundation for a faculty fellowship program to promote public health law education. Ten faculty members from law schools or schools/programs of public health will be selected to participate in a yearlong fellowship program designed to foster innovations in educational programming (including clinical, externship, and other experiential learning) and to build a strong learning community among faculty who teach in the public health law field.

Read More

Symposium on Institutional Corruption and Pharmaceutical Policy

The Edmond J. Safra Center for Ethics at Harvard University has organized a symposium on Institutional Corruption and Pharmaceutical Policy that will be published in the forthcoming issue of the Journal of Law, Medicine & Ethics, 2013: Vol. 14 (3).  It will be published at the begining of September.

The goals of pharmaceutical policy and medical practice are often undermined due to institutional corruption — that is, widespread or systemic practices, usually legal, that undermine an institution’s objectives or integrity. The pharmaceutical industry’s own purposes are often undermined.  In addition, pharmaceutical industry funding of election campaigns and lobbying skews the legislative process that sets pharmaceutical policy. Moreover, certain practices have corrupted medical research, the production of medical knowledge, the practice of medicine, drug safety, and the Food and Drug Administration’s oversight of pharmaceutical marketing.

Marc Rodwin invited a group of scholars to analyze these issues, with each author taking a different look at the sources of corruption, how it occurs and what is corrupted. The articles address five topics: (1) systemic problems, (2) medical research, (3) medical knowledge and practice, (4) marketing, and (5) patient advocacy organizations.

For more information on the symposium, including a full list of the articles, please visit the Safra Center’s website. You can also access advanced copies of the 16 symposium articles through SSRN online.

For a summary of each article and the key themes in the symposium see, Marc Rodwin, Institutional Corruption and Pharmaceutical Policy.

 

Request for Comments from the Presidential Commission for the Study of Bioethical Issues

The Presidential Commission for the Study of Bioethical Issues recently published a “Request for Comments on Issues Related to Incidental Findings That Arise in the Clinical, Research, and Direct-To-Consumer Contexts.” In this publication, the Bioethics Commission requests public comment on “the ethical, legal, and social issues raised by incidental findings that arise from genetic and genomic testing, imaging, and testing of biological specimens conducted in the clinical, research, and direct-to-consumer contexts.” You can read the full “Request for Comments,” which includes instructions on how to submit comments, online here.

Fifth Call for Proposals Now Open

Public Health Law Research has released its fifth call for proposals on studies that focus on the effects of laws and policies on public health.

The new call for proposals is available online: www.rwjf.org/cfp/phlr5

The deadline for submitting proposals is July 24, 2013 at 3 p.m. ET.

As much as $1 million is available in this round of funding for short-term studies. Studies up to 18 months long will be funded at up to $150,000 each.

While PHLR funds studies that mainly focus on the intersection between law and public health, researchers from other disciplines, such as medicine, economics, sociology, psychology, and public policy and administration are encouraged to be part of multi-disciplinary teams of applicants.

PHLR’s previous four calls for proposals were issued in 2009, 2010, 2011, and 2012. Fifty-one studies have been funded to date, addressing a wide range of legal and public health issues, including: the impact of lead laws on public health; effective legal decision-making during public health emergencies; issues related to the public health infrastructure at the state and local levels; the impact of laws on distracted driving and teen driver injury and mortality rates; and many more.

A conference call for applicants will be held June 18, 2013. Applicants are required to register through the RWJF website: www.rwjf.org/cfp/phlr5.

Online Symposium on the Law, Ethics & Science of Re-identification Demonstrations

By Michelle Meyer

Over the course of the last fifteen or so years, the belief that “de-identification” of personally identifiable information preserves the anonymity of those individuals has been repeatedly called up short by scholars and journalists. It would be difficult to overstate the importance, for privacy law and policy, of the early work of “re-identification scholars,” as I’ll call them. In the mid-1990s, the Massachusetts Group Insurance Commission (GIC) released data on individual hospital visits by state employees in order to aid important research. As Massachusetts Governor Bill Weld assured employees, their data had been “anonymized,” with all obvious identifiers, such as name, address, and Social Security number, removed. But Latanya Sweeney, then an MIT graduate student, wasn’t buying it. When, in 1996, Weld collapsed at a local event and was admitted to the hospital, she set out to show that she could re-identify his GIC entry. For twenty dollars, she purchased the full roll of Cambridge voter-registration records, and by linking the two data sets, which individually were innocuous enough, she was able to re-identify his GIC entry. As privacy law scholar Paul Ohm put it, “In a theatrical flourish, Dr. Sweeney sent the Governor’s health records (which included diagnoses and prescriptions) to his office.”

Sweeney’s demonstration led to important changes in privacy law, especially under HIPAA. But that demonstration was just the beginning. In 2006, the New York Times was able to re-identify one individual (and only one individual)  in a publicly available research dataset of the three-month AOL search history of over 600,000 users. The Times demonstration led to a class-action lawsuit (which settled out of court), an FTC complaint, and soul-searching in Congress. That same year, Netflix began a three-year contest, offering a $1 million prize to whomever could most improve the algorithm by which the company predicts how much a particular user will enjoy a particular movie. To enable the contest, Netflix made publicly available a dataset of the movie ratings of 500,000 of its customers, whose names it replaced with numerical identifiers. In a 2008 paper, Arvind Narayanan, then a graduate student at UT-Austin, along with his advisor, showed that by linking the “anonymized” Netflix prize dataset to the Internet Movie Database (IMDb), in which viewers review movies, often under their own names, many Netflix users could be re-identified, revealing information that was suggestive of their political preferences and other potentially sensitive information. (Remarkably, notwithstanding the re-identification demonstration, after awarding the prize in 2009 to a team from AT&T, in 2010, Netflix announced plans for a second contest, which it cancelled only after tussling with a class-action lawsuit (again, settled out of court) and the FTC.) Earlier this year, Yaniv Erlich and colleagues, using a novel technique involving surnames and the Y chromosome, re-identified five men who had participated in the 1000 Genomes Project — an international consortium to place, in an open online database, the sequenced genomes of (as it turns out, 2500) “unidentified” people — who had also participated in a study of Mormon families in Utah.

Most recently, Sweeney and colleagues re-identified participants in Harvard’s Personal Genome Project (PGP), who are warned of this risk, using the same technique she used to re-identify Weld in 1997. As a scholar of research ethics and regulation — and also a PGP participant — this latest demonstration piqued my interest. Although much has been said about the appropriate legal and policy responses to these demonstrations (my own thoughts are here), there has been very little discussion about the legal and ethical aspects of the demonstrations themselves. As a modest step in filling that gap, I’m pleased to announce an online symposium, to take place here at the Bill of Health the week of May 20th, that will address both the scientific and policy value of these demonstrations and the legal and ethical issues they raise. Participants fill diverse stakeholder roles (data holder, data provider — i.e., research participant, re-identification researcher, privacy scholar, research ethicist) and will, I expect, have a range of perspectives on these questions:

Misha Angrist
Madeleine Ball

Daniel Barth-Jones

Yaniv Erlich

Beau Gunderson

Stephen Wilson

Michelle Meyer

Arvind Narayanan

Paul Ohm

Latanya Sweeney

Jennifer Wagner

I hope readers will join us on May 20.

UPDATE: You can call up all of the symposium contributions, in reverse chronological order, by clicking here.

Call for Proposals: Frontiers of Informed Consent

3rd Annual Workshop in Applied Ethics

Northeastern University, Boston, MA, September 27-29, 2013 

Informed, autonomous consent is widely considered to be central to the ethics of human subjects research. However, it remains both conceptually and practically underspecified. A conceptually clear account of informed consent that is appropriate to the broad array of human subjects research, from medical to social science, has been elusive. Moreover, it has proven to be difficult to operationalize informed consent in practice. These challenges to the ethics of informed consent have been compounded by the globalization of research and rapid technological developments.

This interdisciplinary workshop will bring together practitioners and theorists at the leading edge of the ethics of informed consent to share their research and discuss the future of informed consent. The workshop is designed to be highly interactive, and to provide speakers with constructive feedback from colleagues working on related issues.

We invite the submission of abstracts (no more than 750 words) from researchers working on the theoretical and practical challenges of informed consent. Possible topics include, but are not limited to, the following:

  • Conducting research on vulnerable populations
  • Conducting cross-cultural research
  • Conducting research in virtual environments
  • Informed consent and incidental health findings (MRI, genetic)
  • Community health research
  • Community-based participatory research and its challenges to traditional informed consent
  • Community research boards
  • Ethical issues in reporting data to participants
  • When IRBs confuse human subjects protection with research design
  • Genetic testing outside institutional contexts (e.g. mail order)
  • Theories/definitions of informed consent
  • Alternatives to informed consent for human subjects research
  • Theoretical/definitional work on informed consent and its role in human subjects research
  • Informed consent, parental/guardian responsibilities, and minors
  • Extending informed consent to nonhuman research subjects

Please email submissions (and questions) to Ronald Sandler (r.sandler@neu.edu).

The abstract submission deadline is May 1st, 2013. Abstracts will be reviewed by a program committee. Those selected for the program will be asked to submit completed papers one month prior to the workshop, and papers will be made available on the workshop website.  Papers can be of any length, but speakers will be limited to twenty-five minutes to present their ideas, followed by thirty minutes of discussion. For more information about the workshop go to https://www.northeastern.edu/ethics/. This workshop is sponsored by Northeastern’s Ethics Institute, Social Science Environmental Health Research Institute, and Department of Philosophy and Religion.

Health Law and Policy Workshop: Petrie-Flom Fellow Nicholson Price on Making Due in Making Drugs

The Petrie-Flom Center at Harvard Law School is happy to announce the penultimate session of this year’s Health Law Policy, Biotechnology and Bioethics Workshop in the Spring 2013 semester. We’re delighted to welcome a stellar lineup of leading researchers and opinion-makers in the fields at the intersection of health and law.  Professors Elhauge and Cohen lead the 2012-13 workshop series.

This spring’s next presenter is Petrie-Flom Academic Fellow Nicholson Price. He will be presenting his paper “Making Do in Making Drugs: Innovation Policy and Pharmaceutical Manufacturing” on Monday, April 8th  at 5pm in Hauser 105. The full text of the paper is available here, and the abstract is copied below the “read more”

The workshop will conclude on Monday, April 15th with a lecture from WilmerHale Professor of Intellectual Property Law at HLS and Faculty Director of the Berkman Center, Terry Fisher. Workshops are open to the public and copies of papers will generally be posted a week in advance on the Petrie-Flom Website: https://www.law.harvard.edu/programs/petrie-flom/workshop/index.html.

Read More